Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial…

National Institutes of Health is offering a funding call in United States. Applications close on Nov 19, 2026.

Apply on the issuer's website

At a glance

Type
Funding
Offered by
National Institutes of Health (Public funding)
Where
United States
Closes
Nov 19, 2026
How to apply
On the issuer's own website

More from National Institutes of Health

Similar offers in United States

All sections

Edition